Maze Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan 5, 2022--
Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that Jason Coloma, Ph.D, president and chief executive officer of Maze, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 1:30 p.m. ET.
About Maze Therapeutics
Maze Therapeutics is focused on translating genetic insights into new precision medicines for patients with rare diseases and mechanistically defined subsets of common diseases. Maze has developed the MAZE COMPASS™ platform, a proprietary, purpose-built platform that combines human genetic data, functional genomic tools and data science technology to map novel connections between known genes and their influence on susceptibility, timing of onset and rate of disease progression. Using COMPASS, Maze is building a broad portfolio, including wholly owned programs targeting Pompe disease, chronic kidney disease and amyotrophic lateral sclerosis, as well as partnered programs in cardiovascular and ophthalmic diseases. Maze is based in South San Francisco. For more information, please visit mazetx.com, or follow us on LinkedIn.
View source version on businesswire.com:https://www.businesswire.com/news/home/20220105005843/en/
Jillian Connell, Maze Therapeutics
Katie Engleman, 1AB
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH GENETICS PHARMACEUTICAL CARDIOLOGY
SOURCE: Maze Therapeutics
Copyright Business Wire 2022.
PUB: 01/05/2022 04:05 PM/DISC: 01/05/2022 04:06 PM